Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;13:991879. doi: 10.3389/fphar.2022.991879

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Shen, Wang, Xu, Chen, Zhu, Cheng, Fang, Liu and Xu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of metabolic profiles before and after anti-VEGF treatment. (A) Principal component analysis (PCA) model of patients with nAMD before and after anti-VEGF treatment. The PCA model showed no difference. (B) Partial least squares discriminant analysis (PLS-DA) model of patients with nAMD before and after anti-VEGF treatment. The PLS-DA model also showed no difference. (C) The permutation test indicated that PLS-DA model of nAMD overfitted. (D) PCA model of patients with PCV before and after anti-VEGF treatment. The PCA model showed no difference.